Caribou Biosciences to Present New Data Updates from Allogeneic CAR-T Programs in Lymphoma and Multiple Myeloma via Webcast

11/02/2025 – 04:00 PM

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and report the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011, an allogeneic anti-BCMA CAR-T cell therapy, in patients with r/r multiple myeloma. The Company will also report its anticipated pivotal phase 3 trial design for vispa-cel and next steps for the continued clinical development of CB-011.

The announcement comes as Caribou Biosciences seeks to solidify its position in the increasingly competitive CAR-T therapy space. Vispa-cel, with its PD-1 knockout designed to enhance CAR-T cell activity, represents a next-generation approach to allogeneic CAR-T therapy. The market is closely watching the ANTLER trial results to gauge the clinical potential of this strategy, especially in overcoming CAR-T cell exhaustion, a common challenge in treating r/r B-NHL. Initial data has shown some promise, but sustained efficacy and durability remain key endpoints for determining its commercial viability.

CB-011, Caribou’s allogeneic anti-BCMA CAR-T cell therapy for r/r MM, employs a unique “immune cloaking” strategy involving B2M knockout and B2M–HLA-E fusion protein insertion. This approach aims to mitigate immune-mediated rejection, a significant hurdle for allogeneic cell therapies. The CaMMouflage Phase 1 trial’s initial data will be scrutinized for signs that this immune cloaking mechanism is effective, as it could represent a major advancement in expanding the accessibility and efficacy of CAR-T therapies for multiple myeloma patients. The evolving treatment landscape for multiple myeloma includes a range of options, from proteasome inhibitors to immunomodulatory drugs and autologous CAR-T therapies. CB-011’s potential lies in offering an off-the-shelf allogeneic alternative with potentially improved tolerability and accessibility.

Investors and industry analysts will be particularly interested in the Phase 3 trial design for vispa-cel. Factors such as patient selection criteria, primary and secondary endpoints, and comparator arms will provide insights into Caribou’s strategic approach to demonstrating vispa-cel’s superiority over existing treatment options. A well-designed Phase 3 trial is critical for securing regulatory approval and gaining market share in the competitive B-NHL treatment landscape, where established therapies and emerging bispecific antibodies are vying for dominance.

The company’s continued development of CB-011 also attracts high attention. While early-stage, the CaMMouflage trial data could de-risk the platform and provide valuable insights into the broader applicability of Caribou’s genome-editing technology. Furthermore, refinements to manufacturing processes could address some of the challenges that have impacted commercialization of autologous CAR-T therapies. The speed and cost-effectiveness of production will be key factors in determining CB-011’s ultimate market potential.

About vispacabtagene regedleucel
Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL. Additional information on the ANTLER trial (NCT04637763) can be found at clinicaltrials.gov.

About CB-011
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage Phase 1 trial. To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. CB-011 has been granted Fast Track and Orphan Drug designations by the FDA. Additional information on the CaMMouflage trial (NCT05722418) can be found at clinicaltrials.gov.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the Company @CaribouBio and visit www.cariboubio.com.

Analysis: The clinical data presented on November 3, 2025 is poised to be a crucial benchmark for Caribou Biosciences. The Street will be looking for strong signals of efficacy, manageable safety profiles, and evidence that Caribou’s proprietary CRISPR-edited allogeneic CAR-T platform can overcome key limitations associated with earlier generations of cell therapies. Success in either vispa-cel or CB-011 could ignite the stock and validate the company’s approach to next-generation cancer therapeutics.